CompletedNot Applicable

The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals

United States67 participantsStarted 2023-04-25

Plain-language summary

This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Who can participate

Age range40 Years – 120 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Receive AgelessRx's standard Rapamycin treatment protocol * Opted to complete at least 1 blood draw at their local Quest Lab Exclusion Criteria: * Not approved for current AgelessRx standard Rapamycin treatment * History of uncontrolled disease * Unable to complete at least 1 blood draw at their local Quest Lab

What they're measuring

define the relative bioavailability ratio between compounded rapamycin and generic rapamycin

Timeframe: 8 months

Trial details

NCT IDNCT06550271

SponsorAgelessRx

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-12-15

View on ClinicalTrials.gov More Aging trials